Added to YB: 2024-07-26
Pitch date: 2024-07-26
DCTH [bullish]
Delcath Systems, Inc.
+18.65%
current return
Author Info
No bio for this author
Company Info
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
Market Cap
$342.5M
Pitch Price
$8.74
Price Target
30.00 (+189%)
Dividend
N/A
EV/EBITDA
41.20
P/E
281.11
EV/Sales
3.20
Sector
Health Care Equipment and Supplies
Category
growth
Investing Whisperer Stock Ideas - Delcath Systems
DCTH: FDA-approved HEPZATO for liver cancer chemo. $750K/procedure, highly profitable for hospitals. Outpatient use begun. Sales ramping fast. Platform tech for various liver mets. Ocular melanoma 1st indication. $30+ PT in 3-4 yrs. Potential BO target for Boston Scientific. May need small funding for breakeven. Reports Aug 5.
Read full article (1 min)